The multiple sclerosis (MS) pharmaceutical market has increased in the last ten years due to breakthrough immunomodulatory drugs.

Patients now benefit from a wide range of treatment options that effectively manage the condition by reducing the rate of disease progression.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The success of these drugs is represented by the global revenues, which have increased by more than $13bn, from $5.4bn in 2006 to $18.4bn in 2016

Clampdown on Copaxone

The success of MS drugs has been shrouded by controversy. A probe into the MS drug pricing of major companies Bayer, Biogen, Merck, Novartis, Sanofi, Teva, and Roche has shown that several drugs have inflated in price over the years.

Two of the largest price hikes have seen Teva’s Copaxone and Biogen’s Avonex increase by more than 800% to $91,404 and $86,308 respectively.

Legislature Likely?

Congress has a lot of proposals for reigning in Big Pharma and drug pricing, with the majority aiming to tackle the high cost of prescription drugs within the country.

These include accelerating the approval of generic drugs, giving advanced notice for drug price increases, importing lower cost drugs from Canada, and permitting negotiations within government for the pricing of Medicare.

However, years of scrutiny and debate on these issues have so far delayed the passing of pharmaceutical legislature.

Having previously taken a provocative stance on the pharmaceutical industry, Donald Trump's administration is now issuing a favorable executive order for pharmaceutical companies. It is highly possible that drug prices may not be the focus of this order, which has been met with disappointment from Cummings and Welch, who carried out the MS pricing probe.

Turning the Tide

It may now fall to the pharmaceutical companies themselves to reverse the trend and take action on spiraling drug prices.

In March, Roche announced that new entry to the MS market Ocrevus would be priced at a discount to competitors by 25%.

A spokesperson for the company cited the rising drug prices within the disease area as a key reason for this decision.

Either way, those connected to the industry will be keen to see whether the investigations will translate into passable legislature, and whether drugs for other indications are guilty of similar price increases.